دورية أكاديمية
أعرض في EDS

Prognostic and Predictive Value of Immunoscore in Stage III Colorectal Cancer: Pooled Analysis of Cases From the SCOT and IDEA-HORG Studies.

التفاصيل البيبلوغرافية
العنوان: Prognostic and Predictive Value of Immunoscore in Stage III Colorectal Cancer: Pooled Analysis of Cases From the SCOT and IDEA-HORG Studies.
المؤلفون: Domingo E; Department of Oncology, University of Oxford, Oxford, United Kingdom.; CRUK Beatson Institute of Cancer Research, Garscube Estate, Glasgow, United Kingdom., Kelly C; CRUK Glasgow Clinical Trials Unit, University of Glasgow, Glasgow, United Kingdom., Hay J; Glasgow Tissue Research Facility, University of Glasgow, Queen Elizabeth University Hospital, Glasgow, United Kingdom., Sansom O; CRUK Beatson Institute of Cancer Research, Garscube Estate, Glasgow, United Kingdom., Maka N; Glasgow Tissue Research Facility, University of Glasgow, Queen Elizabeth University Hospital, Glasgow, United Kingdom., Oien K; Glasgow Tissue Research Facility, University of Glasgow, Queen Elizabeth University Hospital, Glasgow, United Kingdom., Iveson T; University of Southampton, Southampton, United Kingdom., Saunders M; The Christie NHS Foundation Trust, Manchester, United Kingdom., Kerr R; Department of Oncology, University of Oxford, Oxford, United Kingdom., Tomlinson I; Department of Oncology, University of Oxford, Oxford, United Kingdom., Edwards J; School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom., Harkin A; CRUK Glasgow Clinical Trials Unit, University of Glasgow, Glasgow, United Kingdom., Nowak M; Department of Pathology and Molecular Pathology, Zurich, Switzerland., Koelzer V; Department of Oncology, University of Oxford, Oxford, United Kingdom.; Department of Pathology and Molecular Pathology, Zurich, Switzerland., Easton A; Department of Oncology, University of Oxford, Oxford, United Kingdom., Boukovinas I; Medical Oncology Unit Department, Bioclinic Oncology Unit of Thessaloniki, Thessaloniki, Greece., Moustou E; Pathology, University Hospital of Heraklion, Crete, Greece., Messaritakis I; Laboratory of Translational Oncology, University of Crete-School of Medicine, Heraklion, Greece., Chondrozoumaki M; Laboratory of Tumor Cell Biology, University of Crete - School of Medicine, Heraklion, Greece., Karagianni M; Laboratory of Translational Oncology, University of Crete-School of Medicine, Heraklion, Greece., Pagès F; INSERM, Laboratory of Integrative Cancer Immunology, Sorbonne Université, Université de Paris Cité, Cordeliers Research Center, Paris, France.; Assistance Publique-Hôpitaux de Paris (AP-HP), Immunomonitoring Platform, Georges Pompidou European Hospital, Paris, France., Arnoux F; VERACYTE, Marseille, France., Lautard C; VERACYTE, Marseille, France., Lovera Y; VERACYTE, Marseille, France., Boquet I; VERACYTE, Marseille, France., Catteau A; VERACYTE, Marseille, France., Galon J; INSERM, Laboratory of Integrative Cancer Immunology, Sorbonne Université, Université de Paris Cité, Cordeliers Research Center, Paris, France.; VERACYTE, Marseille, France., Souglakos I; Laboratory of Translational Oncology, University of Crete-School of Medicine, Heraklion, Greece.; Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Greece., Church DN; Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.; Oxford NIHR Comprehensive Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
مؤلفون مشاركون: TransSCOT Consortium
المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Jun 20; Vol. 42 (18), pp. 2207-2218. Date of Electronic Publication: 2024 Mar 14.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE
أسماء مطبوعة: Publication: 2003- : Alexandria, VA : American Society of Clinical Oncology
Original Publication: New York, N.Y. : Grune & Stratton, c1983-
مواضيع طبية MeSH: Colorectal Neoplasms*/drug therapy , Colorectal Neoplasms*/pathology , Colorectal Neoplasms*/mortality , Colorectal Neoplasms*/immunology , Leucovorin*/therapeutic use , Leucovorin*/administration & dosage , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Fluorouracil*/administration & dosage , Fluorouracil*/therapeutic use , Organoplatinum Compounds*/therapeutic use , Organoplatinum Compounds*/administration & dosage , Neoplasm Staging*, Humans ; Female ; Male ; Middle Aged ; Aged ; Prognosis ; Capecitabine/administration & dosage ; Capecitabine/therapeutic use ; Predictive Value of Tests ; Disease-Free Survival ; Oxaliplatin/therapeutic use ; Oxaliplatin/administration & dosage ; Adult ; Chemotherapy, Adjuvant ; Deoxycytidine/analogs & derivatives ; Deoxycytidine/therapeutic use ; Deoxycytidine/administration & dosage
مستخلص: Purpose: Immunoscore (IS) is prognostic in stage III colorectal cancer (CRC) and may predict benefit of duration (6 v 3 months) of adjuvant infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX) chemotherapy. We sought to determine IS prognostic and predictive value in stage-III CRC treated with adjuvant FOLFOX or oral capecitabine and infusional oxaliplatin (CAPOX) in the SCOT and IDEA-HORG trials.
Methods: Three thousand sixty-one cases had tumor samples, of which 2,643 (1,792 CAPOX) were eligible for IS testing. Predefined cutoffs (IS-Low and IS-High) were used to classify cases into two groups for analysis of disease-free survival (3-year DFS) and multivariable-adjusted hazard ratios (mvHRs) by Cox regression.
Results: IS was determined in 2,608 (99.5%) eligible cases, with 877 (33.7%) samples classified as IS-Low. IS-Low tumors were more commonly high-risk (T4 and/or N2; 52.9% IS-Low v 42.2% IS-High; P < .001) and in younger patients ( P = .024). Patients with IS-Low tumors had significantly shorter DFS in the CAPOX, FOLFOX, and combined cohorts (mvHR, 1.52 [95% CI, 1.28 to 1.82]; mvHR, 1.58 [95% CI, 1.22 to 2.04]; and mvHR, 1.55 [95% CI, 1.34 to 1.79], respectively; P < .001 all comparisons), regardless of sex, BMI, clinical risk group, tumor location, treatment duration, or chemotherapy regimen. IS prognostic value was greater in younger (≤65 years) than older (>65 years) patients in the CAPOX cohort (mvHR, 1.92 [95% CI, 1.50 to 2.46] v 1.28 [95% CI, 1.01 to 1.63], P INTERACTION = .026), and in DNA mismatch repair proficient than deficient mismatch repair disease (mvHR, 1.68 [95% CI, 1.41 to 2.00] v 0.67 [95% CI, 0.30 to 1.49], P INTERACTION = .03), although these exploratory analyses were uncorrected for multiple testing. Adding IS to a model containing all clinical variables significantly improved prediction of DFS (likelihood ratio test, P < .001) regardless of MMR status.
Conclusion: IS is prognostic in stage III CRC treated with FOLFOX or CAPOX, including within clinically relevant tumor subgroups. Possible variation in IS prognostic value by age and MMR status, and prediction of benefit from extended adjuvant therapy merit validation.
References: Lancet Oncol. 2022 Jul;23(7):876-887. (PMID: 35636444)
Lancet. 2018 May 26;391(10135):2128-2139. (PMID: 29754777)
J Clin Oncol. 2018 May 20;36(15):1478-1485. (PMID: 29620994)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
J Natl Cancer Inst. 2022 Apr 11;114(4):517-527. (PMID: 34542636)
N Engl J Med. 2018 Mar 29;378(13):1177-1188. (PMID: 29590544)
Ann Oncol. 2020 Oct;31(10):1291-1305. (PMID: 32702383)
J Clin Oncol. 2020 Nov 1;38(31):3638-3651. (PMID: 32897827)
Immunity. 2020 Jan 14;52(1):55-81. (PMID: 31940273)
Nat Rev Cancer. 2020 Nov;20(11):662-680. (PMID: 32753728)
Lancet Oncol. 2021 Jul;22(7):1002-1013. (PMID: 34048685)
Ann Oncol. 2019 Aug 1;30(8):1304-1310. (PMID: 31228203)
Oncoimmunology. 2023 Jan 5;12(1):2161167. (PMID: 36632564)
Ann Oncol. 2022 Nov;33(11):1159-1167. (PMID: 35963480)
Lancet Oncol. 2018 Apr;19(4):562-578. (PMID: 29611518)
N Engl J Med. 2022 Jun 16;386(24):2261-2272. (PMID: 35657320)
Ann Oncol. 2020 Jul;31(7):921-929. (PMID: 32294529)
N Engl J Med. 2004 Jun 3;350(23):2343-51. (PMID: 15175436)
Immunity. 2016 Mar 15;44(3):698-711. (PMID: 26982367)
J Clin Oncol. 2023 Mar 10;41(8):1541-1552. (PMID: 36657089)
JAMA. 2021 Apr 6;325(13):1277-1286. (PMID: 33821899)
J Pathol. 2014 Jan;232(2):199-209. (PMID: 24122236)
Clin Cancer Res. 2020 Oct 1;26(19):5198-5207. (PMID: 32669377)
J Clin Oncol. 2021 Feb 20;39(6):642-651. (PMID: 33356421)
Lancet Oncol. 2020 Dec;21(12):1620-1629. (PMID: 33271092)
فهرسة مساهمة: Investigator: D Church; E Domingo; J Edwards; B Glimelius; I Gogenur; A Harkin; J Hay; T Iveson; E Jaeger; C Kelly; R Kerr; N Maka; H Morgan; K Oien; C Orange; C Palles; C Roxburgh; O Sansom; M Saunders; I Tomlinson
المشرفين على المادة: Q573I9DVLP (Leucovorin)
U3P01618RT (Fluorouracil)
0 (Organoplatinum Compounds)
6804DJ8Z9U (Capecitabine)
04ZR38536J (Oxaliplatin)
0W860991D6 (Deoxycytidine)
SCR Protocol: Folfox protocol
تواريخ الأحداث: Date Created: 20240314 Date Completed: 20240614 Latest Revision: 20240621
رمز التحديث: 20240621
مُعرف محوري في PubMed: PMC11185918
DOI: 10.1200/JCO.23.01648
PMID: 38484206
قاعدة البيانات: MEDLINE
الوصف
تدمد:1527-7755
DOI:10.1200/JCO.23.01648